⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ACRS News
Aclaris Therapeutics, Inc.
Form 8-K
sec.gov
ACRS
Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference
globenewswire.com
ACRS
Excess Share Insurance (ESI) Launches Campio™ Powered by Acrisure®
prnewswire.com
ACRS
Form 8-K
sec.gov
ACRS
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
globenewswire.com
ACRS
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052
globenewswire.com
ACRS
Aclaris Therapeutics to Participate in Two February Healthcare Conferences
globenewswire.com
ACRS
Biosion Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial of BSI-082, a Next-Generation Anti-SIRPα Monoclonal Antibody for Advanced Solid Tumors
prnewswire.com
ACRS
Acres.com Named a 2026 HousingWire Tech100 Winner for Transforming Land Intelligence in Homebuilding and Real Estate
globenewswire.com
ACRS
Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)
globenewswire.com
ACRS